NMPA Approvals Tracker: China Drug Approvals 2026

How to Read NMPA Approvals

Searching “NMPA approval news today” returns a stream of company press releases and regulator notices that are easy to read as a simple list of wins. For a cross-border dealmaker, that is the wrong lens. An NMPA approval is a data point about where de-risked, licensable assets are forming — and reading it well means knowing what kind of approval it is, who originated the asset, and whether it is the sort of thing global pharma will pay to license out of China.

The first thing to establish on any approval is the pathway. A drug cleared on a full Phase 3 package reads very differently from one cleared conditionally on early data. The second is provenance: a first-in-class molecule originated by a domestic developer is a far stronger out-licensing signal than an imported product approved after its FDA debut. The third is therapeutic area, because the competitive intensity of a China asset depends heavily on whether it sits in a crowded lane like PD-1 or a contested one like obesity.

A useful mental model is to sort each approval into one of three types: a first-in-class or best-in-class domestic approval, the high-signal events worth pursuing; an imported approval of a multinational’s product, which matters for market access but rarely creates an out-licensing opportunity; or an incremental approval — a biosimilar, new dosage form or me-too entrant — which adds to the count but carries little BD signal. For the underlying mechanics, see our NMPA drug approval process guide.

The Expedited Pathways That Matter

China’s Provisions for Drug Registration set out the expedited procedures, run through the Center for Drug Evaluation (CDE). When you read an approval notice, these labels tell you how the regulator treated the asset. All timelines are in working days.

• Breakthrough therapy designation: during clinical trials, for drugs for serious diseases with no effective treatment or a clear clinical advantage. It brings CDE consultation at key stages and staged data review.
• Conditional approval: marketing on clinical data that predict benefit, for serious diseases without effective treatment or urgent public-health needs. Post-approval studies are required, and if they are not completed on time the NMPA can act up to revoking the approval (Article 67).
• Priority review: a 130-day review clock for the marketing application, or 70 days for urgently needed rare-disease drugs already marketed abroad. Breakthrough and conditionally approved drugs, rare-disease and paediatric products qualify.
• Special review: for public-health emergencies.
• Faster trial starts: IND decisions within 60 days, and within 30 days for eligible Class 1 innovative drugs since NMPA Announcement No. 86 of September 2025.

2026 So Far

By the end of June 2026 the NMPA had approved 2,318 drug registration applications, including 38 globally new (Class 1) innovative drugs. The regulator also reported that the 11 new-target, new-mechanism drugs approved in the first half equalled the total for all of 2025 — and that all 11 were developed in China, against four of 11 in 2025.

Notable 2026 approvals, each checked against the company announcement or a trade report of it:

Four of these are world firsts: ecnoglutide, satri-cel and iza-bren are the first approvals of their kind anywhere, and China was the first country to approve felzartamab. Two carry direct deal links: Bristol Myers Squibb partners on iza-bren outside China, and Biogen licensed felzartamab’s Greater China rights from TJ Biopharma in April 2026 — four months before the approval. Satri-cel takes CAR-T therapy into solid tumours, where no CAR-T had been approved anywhere before.

The 2025 Record Year

Two counts describe 2025, and both were records. The NMPA’s own count is 76 innovative drugs — 47 chemical drugs, 23 biologics and six traditional Chinese medicines — up from 48 in 2024, with 11 first-in-class medicines, four of them developed by Chinese companies. PharmCube’s broader count, published in DIA Global Forum, covers every drug receiving its first marketing authorization in China excluding traditional Chinese medicines: 120 new drugs, triple digits for the first time.

• 61 first global approvals in China. Half of the new drugs reached patients in China before anywhere else, including five molecules from US originators.
• 63 from domestic developers. Local products (52%) outnumbered imports (57) for the first time, and domestic innovation accounted for 81% of the increase in new entrants.
• Landmark domestic approvals included the molecules below.

What the Approvals Reveal

The 2025 approval set tells a consistent story about where China’s innovation is concentrated — and therefore where the licensable assets come from.

• Oncology is the centre of gravity. Cancer remained the most active area, with new targeted therapies, radiopharmaceuticals and haematology drugs.
• Small molecules still lead by count. They made up 60% of new drugs (72 products) and monoclonal antibodies 15% (18). Bispecifics and peptides had four entrants each; ADCs, cell therapies and fusion proteins three each — the modalities that drive the largest deals are not yet the bulk of the count.
• Metabolic and immunology are rising. Cardiovascular and metabolic disease was the other main area in 2025, led by mazdutide, and 2026 added ecnoglutide.

What Approvals Signal for Out-Licensing

The core thesis of this tracker: an NMPA approval — or a late-stage NMPA filing — is the clearest de-risking event for a China asset, and a leading indicator of out-licensing supply. Approval turns a preclinical story into a regulator-reviewed asset with human data from China’s fast clinical system, which is the profile global pharma pays for.

The deal data is consistent with it. The NMPA reported more than $130 billion of out-licensing deals across more than 150 transactions in 2025, up from $51.9 billion across 94 in 2024. PharmCube counts $139.4 billion between January and 8 October 2026, already above 2025. Our China outbound licensing tracker logs the largest of those deals.

An approval is necessary but not sufficient. A China approval does not on its own guarantee a clean ex-China licence: the buyer still has to confirm that the clinical package will satisfy the FDA and EMA, that the IP is clean, and that the rights are available. See our China licensing opportunities guide for how rights are split in practice.

Reading the Filing Pipeline

An approval is a lagging indicator; the filing and designation pipeline leads it. Read three layers in sequence: (1) breakthrough therapy designations, which flag differentiated assets during development; (2) marketing-application acceptances and priority review grants, which put an asset on a defined review clock — 130 working days under priority review; and (3) approvals, which confirm the asset. Engaging at the first or second layer is where the value is captured. China’s fast clinical system compresses the time between layers; we cover that in our analysis of China’s clinical trial advantages.

What to Watch Next

• Whether 2026 beats 2025. With 38 Class 1 approvals in the first half against 76 in all of 2025, the year is on a comparable pace, and the new-mechanism count has already matched it.
• Global firsts from China. Satri-cel and iza-bren were first approvals anywhere; watch for more China-first approvals of partnered assets.
• Metabolic depth. After mazdutide and ecnoglutide, more incretin and combination assets are moving through the NMPA — the area where Western buyers are most active.
• Conditional approvals converting. Iza-bren and tinengotinib were approved conditionally; whether confirmatory studies convert them to full approval is a diligence checkpoint for any licensee.

For the broader news context — financings, listings and policy — see our running China biotech news coverage.

How We Use This Tracker

At Vision Lifesciences, the NMPA approval and filing feed is an input to sourcing, not an end in itself. When a notable first-in-class asset earns breakthrough designation, files for approval or is approved, it enters our screen as a potential licensing candidate. We then check what the headline cannot: whether the clinical package will translate to FDA and EMA standards, whether the IP holds up, whether rights outside China are available, and whether the originator is a realistic counterparty. If you are tracking a specific NMPA approval or filing, see our in-licensing service or talk to our team.

Frequently Asked Questions

Methodology & Sources

Approval statistics come from the NMPA as reported by official and state media, and from PharmCube’s count published in DIA Global Forum; the two use different definitions and are not combined. Notable approvals were selected for their out-licensing or strategic signal and checked against the company announcement or a trade report of it, linked in the table. Pathway rules are taken from the NMPA’s published texts.

Sources:

1. Vision Lifesciences research: our own deal tracking and insights from our day-to-day cross-border licensing and M&A advisory work (about us)
2. Company announcements for each approval, linked above
3. Xinhua via Bastille Post, China approves 38 globally new innovative drugs in first half of 2026 (NMPA briefing, Jul 2026)
4. Guangming Online, China approves record number of innovative drugs in 2025 (NMPA figures, 23 Jan 2026)
5. DIA Global Forum, 2025 NMPA approvals: China clears record number of new drugs (PharmCube data, Mar 2026)
6. NMPA, Provisions for Drug Registration, Chapter IV (expedited procedures)
7. NMPA, Announcement [2025] No. 86 (30-working-day IND pathway)
8. OncLive, China’s NMPA approves iza-bren for pretreated recurrent/metastatic ESCC (Jul 2026)
9. TipRanks / The Fly, Akeso reports ivonescimab receives NMPA approval to treat NSCLC (Apr 2025)
10. Reuters Breakingviews, China biotech’s ingenuity extends to dealmaking (16 Oct 2026; PharmCube data)